Hobbs, F. D. Richard
Montgomery, Hugh
Padilla, Francisco
Simón-Campos, Jesus Abraham
Arbetter, Douglas
Seegobin, Seth
Kiazand, Alexandre
Streicher, Katie
Martinez-Alier, Nuria
Cohen, Taylor S.
Esser, Mark T.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial
https://doi.org/10.1007/s40121-024-00931-4
Funding for this research was provided by:
AstraZeneca
Article History
Received: 6 December 2023
Accepted: 24 January 2024
First Online: 25 February 2024
Declarations
:
: F.D. Richard Hobbs has received funding from AstraZeneca to cover meeting attendances and operationalization of TACKLE in the UK as the UK Principal Investigator. He has received funding from UK Research and Innovation and the National Institute for Health and Care Research (NIHR) for national Urgent Public Heath COVID-19 trials and directorship of the NIHR Applied Research Collaboration, Oxford Thames Valley. Hugh Montgomery has received funding from the UK NIHR BRC at University College London Hospitals. He has received consultation fees from AstraZeneca and has been a consultant for Millfield Medical Ltd. During the development of a new Closed Circuit Continuous Positive Airway Pressure machine. Francisco Padilla has received personal fees and grants from Amgen, AstraZeneca, Boehringer Ingelheim, Ferrer, Kowa, Medix, Merck, Merck Sharp and Dohme, Novartis, Pfizer, Sanofi, Servier, and Silanes. Jesus Abraham Simón-Campos has served on advisory boards for Pfizer, AstraZeneca, Roche, Regeneron, Atea, and Eli Lilly, is a speaker for Pfizer, AstraZeneca, Roche, and Regeneron, and has received funding from AstraZeneca, Roche, and Pfizer to cover meeting attendances. Douglas Arbetter, Seth Seegobin, Alexandre Kiazand, Katie Streicher, Taylor S. Cohen, and Mark T. Esser are employees of, and may hold stock and/or stock options in, AstraZeneca. Nuria Martinez-Alier was an employee of AstraZeneca at the time of this analysis. Dr Martinez Alier’s current affiliation is: Department of Paediatric Infectious Diseases and Immunology, Evelina London Children’s Hospital, Guy’s and St Thomas’ NHS Foundation Trust, London, UK.
: The study adhered to Good Clinical Practice guidelines and the Declaration of Helsinki, Council for International Organizations of Medical Sciences International Ethical guidelines, applicable International Conference on Harmonisation Good Clinical Practice guidelines, and all applicable laws and regulations. The protocol was reviewed and approved by an institutional review board or ethics committee at the respective study sites (Table InternalRef removed). All participants provided informed, written consent.